iCo IND accepted

Article

The FDA has accepted iCoTherapeutics' Investigational New Drug (IND) application for iCo-007.

The FDA has accepted iCoTherapeutics' Investigational New Drug (IND) application for iCo-007, a treatment for diabetic macular oedema (DME).

iCo-007 is a second generation antisense compound that targets c-Raf kinase messenger RNA and reduces the oedema by decreasing the signalling of growth factors such as VEGF that signal through the c-Raf kinase pathway.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
Related Content
An ophthalmologist screens a young woman at a testing device. Image credit: ©Friends Stock – stock.adobe.com

For younger patients with mid-range myopia, consider phakic IOLs

May 17th 2024
Article

The implantable lenses can offer an advantage over laser surgery

A turquoise cell structure under a microscope. Image credit: ©Marharyta – stock.adobe.com

The good, the bad and the maybe in ocular gene therapies

May 15th 2024
Article

Promising innovations are not one-size-fits-all

Syringes of various sizes, stored in a clinic. Image credit: ©Sergey Ryzhov – stock.adobe.com

Outlook Therapeutics submits UK Marketing Authorisation Application for wet AMD treatment

May 13th 2024
Article

The submission for bevacizumab gamma (ONS-5010/LYTENAVA) follows a positive opinion from the CHMP in March

Image credit: ©Vitechek – stock.adobe.com

Going beyond the clinical setting in ophthalmic mentorship

May 9th 2024
Article

Three leaders in glaucoma research, retina care and refractive surgery share their expertise

Two eyeballs in two mirrors. Image created with Canva AI.

Keratometry and total keratometry values are similar in healthy eyes

May 8th 2024
Article

Astigmatic values differed between K and TK readings

Image by Jennifer Toomey/MJH Life Sciences using Adobe Firefly AI

Reconfiguring treatment goals for paediatric myopia around ocular development

May 8th 2024
Article

Considering ages and stages of myopia progression in a therapeutic timeline

© 2024 MJH Life Sciences

All rights reserved.